Network


Latest external collaboration on country level. Dive into details by clicking on the dots.

Hotspot


Dive into the research topics where Lauren A Williams is active.

Publication


Featured researches published by Lauren A Williams.


Stroke | 2015

Surgeon Case Volume and 30-Day Mortality After Carotid Endarterectomy Among Contemporary Medicare Beneficiaries Before and After National Coverage Determination for Carotid Artery Stenting

Hiraku Kumamaru; Jessica J. Jalbert; Louis L. Nguyen; Marie Gerhard-Herman; Lauren A Williams; Chih-Ying Chen; John D. Seeger; Jun Liu; Jessica M. Franklin; Soko Setoguchi

Background and Purpose— After the 2005 National Coverage Determination to reimburse carotid artery stenting (CAS) for Medicare beneficiaries, the number of CAS procedures increased and carotid endarterectomy (CEA) decreased. We evaluated trends in surgeons’ past-year CEA case-volume and 30-day mortality after CEA, and their association before and after the National Coverage Determination. Methods— In a retrospective cohort study of patients undergoing CEA (2001–2008) and CAS (2005–2008) using Medicare data, we described yearly trends of CEA and CAS rates, patient characteristics, and 30-day mortality after CEA. We used logistic regression adjusting for patient- and surgeon-level factors to assess the effect of surgeon case volume on 30-day mortality after CEA. Results— We identified 454 717 CEA and 27 943 CAS patients. Patients undergoing CEA in recent years were older and had more comorbidities than earlier years. CEA rates per 10 000 beneficiaries declined from 18.1 in 2002 to 12.7 in 2008, whereas median surgeon past-year case-volume declined from 27 to 21. The CAS rates peaked at 2.3 per 10 000 beneficiaries in 2006 but declined to 1.8 in 2008, resulting in declining overall revascularization procedure rates during 2005 to 2008. Thirty day post-CEA mortality was 1.40% (95% confidence interval, 1.34–1.47) in 2001 to 2002 and 1.17% (1.10–1.24) in 2007 to 2008. Surgeon’s past-year case-volume of <10 was associated with higher 30-day mortality consistently during 2001 to 2008. Conclusions— The rate of CEA procedures decreased substantially during 2001 to 2008, as did surgeon past-year case-volume. The postprocedural mortality in Medicare beneficiaries was high compared with trial patients but somewhat improved over time. Those operated by lower past-year case-volume surgeons had increased mortality.


Circulation-cardiovascular Quality and Outcomes | 2014

Validity of Deterministic Record Linkage Using Multiple Indirect Personal Identifiers: Linking a Large Registry to Claims Data

Soko Setoguchi; Ying Zhu; Jessica J. Jalbert; Lauren A Williams; Chih-Ying Chen

Background—Linking patient registries with administrative databases can enhance the utility of the databases for epidemiological and comparative effectiveness research. However, registries often lack direct personal identifiers, and the validity of record linkage using multiple indirect personal identifiers is not well understood. Methods and Results—Using a large contemporary national cardiovascular device registry and 100% Medicare inpatient data, we linked hospitalization-level records. The main outcomes were the validity measures of several deterministic linkage rules using multiple indirect personal identifiers compared with rules using both direct and indirect personal identifiers. Linkage rules using 2 or 3 indirect, patient-level identifiers (ie, date of birth, sex, admission date) and hospital ID produced linkages with sensitivity of 95% and specificity of 98% compared with a gold standard linkage rule using a combination of both direct and indirect identifiers. Conclusions—Ours is the first large-scale study to validate the performance of deterministic linkage rules without direct personal identifiers. When linking hospitalization-level records in the absence of direct personal identifiers, provider information is necessary for successful linkage.


Journal of the American College of Cardiology | 2013

Impact of Baseline Heart Failure Burden on Post-Implantable Cardioverter-Defibrillator Mortality Among Medicare Beneficiaries

Chih-Ying Chen; Lynne W. Stevenson; Garrick C. Stewart; John D. Seeger; Lauren A Williams; Jessica J. Jalbert; Soko Setoguchi

OBJECTIVES This study sought to assess the impact of baseline heart failure (HF) burden on survival with primary implantable cardioverter-defibrillator (ICD) among Medicare recipients. BACKGROUND Survival after primary ICD implantation may differ between trial and Medicare populations. METHODS Linking data from the CMS (Centers for Medicare and Medicaid Services) ICD registry and the Medicare files (2005 to 2009), we identified primary ICD recipients age ≥66 years with ejection fraction ≤35%. Number of previous HF hospitalizations (prev-HF-hosp) and length of hospitalization prior to implantation were used to define HF burden. Crude all-cause mortality was estimated. Adjusted hazard ratios (HR) were derived from Cox models. RESULTS Of 66,974 ICD recipients (73% men, 88% white, mean age 75 years), 11,876 died (average follow-up = 1.4 years), with 3-year mortality of 31%. Among patients with no prev-HF-hosp, 3-year mortality was 27% compared with 63% in those with ≥3 prev-HF-hosp (adjusted HR: 1.8). Among patients with same-day implantation, 3-year mortality was 25% compared with 53% in those with >1-week hospitalization days prior to implantation (adjusted HR: 1.9). Mortality at 3-year follow-up among the 31,685 ICD recipients with no prev-HF-hosp and same-day implantation (low HF burden) was similar to that in trials (22%). CONCLUSIONS Nearly one-third of Medicare ICD recipients died within 3 years, reflecting a population with more advanced age and disease than seen in trial populations for primary prevention ICD. Nearly one-half of Medicare recipients had a low HF burden and had a survival similar to trial ICD recipients. Future research is warranted to understand the effectiveness of primary ICD implantation among Medicare beneficiaries with heavy HF burdens.


BMJ | 2015

Real world effectiveness of primary implantable cardioverter defibrillators implanted during hospital admissions for exacerbation of heart failure or other acute co-morbidities: cohort study of older patients with heart failure

Chih-Ying Chen; Lynne Warner Stevenson; Garrick C. Stewart; Deepak L. Bhatt; Manisha Desai; John D. Seeger; Lauren A Williams; Jessica J. Jalbert; Soko Setoguchi

Objectives To examine the effectiveness of primary implantable cardioverter defibrillators (ICDs) in elderly patients receiving the device during a hospital admission for exacerbation of heart failure or other acute co-morbidities, with an emphasis on adjustment for early mortality and other factors reflecting healthy candidate bias rather than the effect of the ICD. Design Retrospective cohort study. Setting Linked data from the Centers for Medicare and Medicaid Services and American College of Cardiology-National Cardiovascular Data Registry ICD registry, nationwide heart failure registry, and Medicare claims data 2004-09. Population 23 111 patients aged ≥66 who were admitted to hospital for exacerbation of heart failure or other acute co-morbidities and eligible for primary ICDs. Main outcome measures All cause mortality and sudden cardiac death. Latency analyses with Cox regression were used to derive crude hazard ratios and hazard ratios adjusted for high dimension propensity score for outcomes after 180 days from index implantation or discharge. Results Patients who received an ICD during a hospital admission had lower crude mortality risk than patients who did not receive an ICD (40% v 60% at three years); however, with conditioning on 180 day survival and with adjustment for high dimension propensity score, the apparent benefit with ICD was no longer evident for sudden cardiac death (adjusted hazard ratio 0.95, 95% confidence interval 0.78 to 1.17) and had a diminished impact on total mortality (0.91, 0.82 to 1.00). There were trends towards a benefit with ICD in reducing mortality or sudden cardiac death in patients who had had a myocardial infarction more than 40 days previously, left bundle branch block, or low serum B type natriuretic peptide; however, these trends did not reach significance. Conclusion After adjustment for healthy candidate bias and confounding, the benefits of primary ICD therapy seen in pivotal trials were not apparent in patients aged 66 or over who received ICDs during a hospital admission for exacerbation of heart failure or other acute co-morbidities. Future research is warranted to further identify subgroups of elderly patients who are more likely to benefit from ICDs. Recognition of those patients whose dominant risk factors are from decompensated heart failure and non-cardiac co-morbidities will allow better focus on ICDs in those patients for whom the device offers the most benefit and provides meaningful prolonging of life.


BMJ | 2014

Influence of healthy candidate bias in assessing clinical effectiveness for implantable cardioverter-defibrillators: cohort study of older patients with heart failure

Soko Setoguchi; Lynne Warner Stevenson; Garrick C. Stewart; Deepak L. Bhatt; Andrew E. Epstein; Manisha Desai; Lauren A Williams; Chih-Ying Chen

Objective To assess the potential contribution of unmeasured general health status to patient selection in assessments of the clinical effectiveness of implantable cardioverter-defibrillator (ICD) therapy. Design Retrospective cohort study. Setting Linked data from an ICD registry, heart failure registry, and Medicare claims data for ICDs implanted in 2005 through 2009. Participants 29 426 patients admitted to hospital with heart failure aged 66 years or older and eligible for ICD therapy for primary prevention. Main outcome measures Non-traumatic hip fracture, admission to a skilled nursing facility, and 30 day mortality—outcomes unlikely to be improved by ICD therapy. Results Compared with 17 853 patients without ICD therapy, 11 573 patients with ICD therapy were younger and had lower ejection fraction and more cardiac admissions to hospital but fewer non-cardiac admissions to hospital and comorbid conditions. Patients with ICD therapy had greater freedom from unrelated events after adjusting for age and sex: hip fracture (hazard ratio 0.77, 95% confidence interval 0.64 to 0.92), skilled nursing facility admission (0.53, 0.50 to 0.55), and 30 day mortality (0.12, 0.10 to 0.15). Conclusions Lower risks of measured outcomes likely reflect unmeasured differences in comorbidity and frailty. The findings highlight potential pitfalls of observational comparative effectiveness research and support physician consideration of general health status in selecting patients for ICD therapy.


Circulation-cardiovascular Quality and Outcomes | 2016

Comparative Effectiveness of Carotid Artery Stenting Versus Carotid Endarterectomy Among Medicare Beneficiaries

Jessica J. Jalbert; Louis L. Nguyen; Marie Gerhard-Herman; Hiraku Kumamaru; Chih Ying Chen; Lauren A Williams; Jun Liu; Andrew T. Rothman; Michael R. Jaff; John D. Seeger; James F. Benenati; Peter Schneider; Herbert D. Aronow; Joseph A. Johnston; Thomas G. Brott; Thomas T. Tsai; Christopher J. White; Soko Setoguchi

Background—Effectiveness of carotid artery stenting (CAS) relative to carotid endarterectomy (CEA) among Medicare patients has not been established. We compared effectiveness of CAS versus CEA among Medicare beneficiaries. Methods and Results—We linked Medicare data (2000–2009) to the Society for Vascular Surgery’s Vascular Registry (2005–2008) and the National Cardiovascular Data Registrys (NCDR) Carotid Artery Revascularization and Endarterectomy Registry (2006–2008/2009). Medicare patients were followed up from procedure date until death, stroke/transient ischemic attack, periprocedural myocardial infarction, or a composite end point for these outcomes. We derived high-dimensional propensity scores using registry and Medicare data to control for patient factors and adjusted for provider factors in a Cox regression model comparing CAS with CEA. Among 5254 Society for Vascular Surgery’s Vascular Registry (1999 CAS; 3255 CEA) and 4055 Carotid Artery Revascularization and Endarterectomy Registry (2824 CAS; 1231 CEA) Medicare patients, CAS patients had a higher comorbidity burden and were more likely to be at high surgical risk (Society for Vascular Surgery’s Vascular Registry: 96.7% versus 44.5%; Carotid Artery Revascularization and Endarterectomy Registry: 71.3% versus 44.7%). Unadjusted outcome risks were higher for CAS. Mortality risks remained elevated for CAS after adjusting for patient-level factors (hazard ratio, 1.24; 95% confidence interval, 1.06–1.46). After further adjustment for provider factors, differences between CAS and CEA were attenuated or no longer present (hazard ratio for mortality, 1.13; 95% confidence interval, 0.94–1.37). Performance was comparable across subgroups defined by sex and degree of carotid stenosis, but there was a nonsignificant trend suggesting a higher risk of adverse outcomes in older (>80) and symptomatic patients undergoing CAS. Conclusions—Outcomes after CAS and CEA among Medicare beneficiaries were comparable after adjusting for both patient- and provider-level factors.


Circulation-cardiovascular Quality and Outcomes | 2015

Relationship Between Physician and Hospital Procedure Volume and Mortality After Carotid Artery Stenting Among Medicare Beneficiaries

Jessica J. Jalbert; Marie Gerhard-Herman; Louis L. Nguyen; Michael R. Jaff; Hiraku Kumamaru; Lauren A Williams; Chih Ying Chen; Jun Liu; John D. Seeger; Andrew T. Rothman; Peter Schneider; Thomas G. Brott; Thomas T. Tsai; Herbert D. Aronow; Joseph A. Johnston; Soko Setoguchi

Background—Clinical trials demonstrated the efficacy of carotid artery stenting (CAS) relative to carotid endarterectomy when performed by physicians with demonstrated proficiency. It is unclear how CAS performance may be influenced by the diversity in CAS and non-CAS provider volumes in routine clinical practice. Methods and Results—We linked Medicare claims to the Centers for Medicare and Medicaid Services’ CAS Database (2005–2009). We assessed the association between 30-day mortality and past-year physician (0, 1–4, 5–9, 10–19, ≥20) and hospital (<10, 10–19, 20–39, ≥40) CAS volumes and past-year hospital coronary and peripheral stenting volumes (<200, 200–399, 400–849, ≥850) among beneficiaries at least 66 years of age. Unadjusted 30-day mortality risk was 1.8% (95% confidence interval [CI], 1.6–2.0) for 19 724 patients undergoing CAS by 2045 physicians in 729 hospitals. Median past-year CAS volume was 9 (interquartile range, 4–19) for physicians and 23 (interquartile range, 12–41) for hospitals. Compared to physicians performing ≥20 CAS in the past year, lower CAS volumes were associated with higher adjusted risks of 30-day morality (P value for trend < 0.05): 1.4 (95% CI, 0.9–2.3) for 0 past-year CAS, 1.3 (95% CI, 0.9–1.8) for 1 to 4, 1.1 (95% CI, 0.8–1.6) for 5 to 9, and 0.9 (95% CI, 0.7–1.4) for 10 to 19. An inverse relationship between 30-day mortality and past-year CAS hospital volume as well as past-year hospital non-CAS volume, past-year hospital non-CAS volume, and 30-day mortality was also noted. Conclusions—Among Medicare patients, an inverse relationship exists between physician and hospital CAS volumes and hospital non-CAS stenting volume and 30-day mortality, even after adjusting for all pertinent patient- and hospital-level factors.


Journal of the American College of Cardiology | 2012

BASELINE BURDEN OF HEART FAILURE LIMITS DURATION OF BENEFIT OF ICD FOR MEDICARE RECIPIENTS

Chih-Ying Chen; Lynne Warner Stevenson; John D. Seeger; Lauren A Williams; Jessica J. Jalbert; Andrew T. Rothman; Garrick C. Stewart; Soko Setoguchi

Survival after primary ICD implantation may differ between trial evidence and Medicare patients, for whom we determined survival after primary ICD in relation to the baseline heart failure (HF) burden. Linking data from the CMS ICD registry and Medicare files (2005-2008), we identified 66,974 (73&


JAMA Neurology | 2015

Outcomes After Carotid Artery Stenting in Medicare Beneficiaries, 2005 to 2009

Jessica J. Jalbert; Louis L. Nguyen; Marie Gerhard-Herman; Michael R. Jaff; Christopher J. White; Andrew T. Rothman; John D. Seeger; Hiraku Kumamaru; Lauren A Williams; Chih Ying Chen; Jun Liu; Thomas T. Tsai; Herbert D. Aronow; Joseph A. Johnston; Thomas G. Brott; Soko Setoguchi


Pain Physician | 2014

Opioid tolerance--a predictor of increased length of stay and higher readmission rates.

Padma Gulur; Lauren A Williams; Chaudhary S; Katharine Koury; Michael R. Jaff

Collaboration


Dive into the Lauren A Williams's collaboration.

Top Co-Authors

Avatar
Top Co-Authors

Avatar

Jessica J. Jalbert

Brigham and Women's Hospital

View shared research outputs
Top Co-Authors

Avatar

Chih-Ying Chen

Brigham and Women's Hospital

View shared research outputs
Top Co-Authors

Avatar

John D. Seeger

Brigham and Women's Hospital

View shared research outputs
Top Co-Authors

Avatar

Jun Liu

Brigham and Women's Hospital

View shared research outputs
Top Co-Authors

Avatar

Louis L. Nguyen

Brigham and Women's Hospital

View shared research outputs
Top Co-Authors

Avatar

Marie Gerhard-Herman

Brigham and Women's Hospital

View shared research outputs
Top Co-Authors

Avatar
Top Co-Authors

Avatar

Garrick C. Stewart

Brigham and Women's Hospital

View shared research outputs
Top Co-Authors

Avatar
Researchain Logo
Decentralizing Knowledge